Yonhap Infomax NewsPharmAbcine Inc., facing potential delisting, has invested KRW 10 billion ($7.6 million) to establish Symbance, aiming to enter the venture investment sector by securing a New Technology Business Finance Company license, though regulatory disclosure remains pending.
#YonhapInfomax #PharmAbcine #Symbance #VentureInvestment #NTBFC #DisclosureObligation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=99694
#YonhapInfomax #PharmAbcine #Symbance #VentureInvestment #NTBFC #DisclosureObligation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=99694
'Delisting Threat' PharmAbcine Invests KRW 10 Billion to Establish 'Symbance'—Strategic Move into Venture Investment
PharmAbcine Inc., facing potential delisting, has invested KRW 10 billion ($7.6 million) to establish Symbance, aiming to enter the venture investment sector by securing a New Technology Business Finance Company license, though regulatory disclosure remains pending.